Action mechanism and signal pathways of psidium guajava L. aqueous extract in killing prostate cancer LNCaP cells

Nutrition and Cancer

Volumn 62, Issue 2, 2010, Pages 260-270

  Chen, Kuan Chou ^a   Peng, Chiung Chi ^b   Chiu, Wen Ta ^c   Cheng, Yu Ting ^d   Huang, Guan Ta ^d   Hsieh, Chiu Lan ^e   Peng, Robert Y ^c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d HUNGKUANG UNIVERSITY   (Taiwan)

^e NATIONAL CHANGHUA UNIVERSITY OF EDUCATION   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GUAVA EXTRACT; LACTATE DEHYDROGENASE; METRIBOLONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; NICK END LABELING; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; HUMANS; L-LACTATE DEHYDROGENASE; MALE; METRIBOLONE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; PLANT EXTRACTS; PLANT LEAVES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PSIDIUM; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

PSIDIUM GUAJAVA;

EID: 76749137291     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903407130     Document Type: Article

References (42)

1. Peng RY, Hsieh CL, Chen KC (eds.): Review on the medicinal uses of Psidium guajava L. In Recent Progress in Medicinal Plants (Chief Editor: J. N. Govil, Division of Genetics, Indian Agricultural Research Institute, New Delhi), 20, 215-248, 2008.
2. Hsieh CL, Lin YC, Yen GC, and Chen HY: Preventive effects of guava (Psidium guajava L.) leaves and its active compounds against ?-dicarbonyl compounds-induced blood coagulation Food Chem 103, 528-535, 2007.
3. Yamashiro S, Noguchi K, Matsuzaki T, Miyagi K, Nakasone J, et al.: Cardioprotective effects of extracts from Psidium guajava L. and Limonium wrightii, Okinawan medicinal plants, against ischemia-reperfusion injury in perfused rat hearts. Pharmacology 67, 128-135, 2003.
4. Hsieh CL, Lin YC, Ko WS, Peng CH, Huang CN, et al.: Inhibitory effect of some selected nutraceutic herbs on LDL glycation induced by glucose and glyoxal. J Ethnopharmacol 102, 357-363, 2005.
5. Chen KC, Hsieh CL, Peng CC, Hsieh-Li HM, Chiang HS, et al.: Brain derived metastatic prostate cancer DU-145 cells are effectively inhibited in vitro by guava (Psidium gujava L.) leaf extracts. Nutr Cancer 58, 93-106, 2007.
6. Hsieh CL, Huang CN, Lin YC, Peng RY: Molecular action mechanism against apoptosis by aqueous extract from guava budding leaves elucidated with human umbilical vein endothelial cell (HUVEC) model. J Agric Food Chem 55, 8523-8533, 2007.
7. Krook M, Ghosh D, Stromberg R, Carlquist M, Jornvall H: Carboxyethyllysine in a protein: native carbonyl reductase/NADP+-dependent prostaglandin dehydrogenase. Biochem 90, 502-506, 1993.
8. Jaiarj P,Wongkrajang Y, Thongpraditchote S, Peungvicha P, Bunyapraphatsara N, et al.: Guava leaf extract and topical haemostasis. Phytother Res 14, 388-391, 2000.
9. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, et al.: Pathogenesis of the atherosclerosis lesion. Implication for diabetes mellitus. Diabets Care 15, 1156-1167, 1992.
10. Kikuchi S, Shinpo K, Takeuchi M, Yamagishi S, Makita Z, et al.: Glycation-a sweet tempter for neuronal death. Brain Res Brain Res Rev 41, 306-323, 2003.
11. Ishiguro HN, Nakaigawa Y, Miyoshi K, Fujinami Y, Kubota H. et al.: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64, 92-100, 2005.
12. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al.: Cancer statistics, 2007. CA Cancer J Clin 57, 43-66, 2007.
13. So A, Gleave M, Hurtado-Col A, Nelson C: Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23, 1-9, 2005.
14. Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K, et al.: Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int J Urol 13, 593-600, 2006.
15. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174, 2002.
16. Chen KC, Peng CC, Peng RY, Su CH, Chiang HS, et al.: Unique formosan mushroom Antrodia camphorata differentially inhibits androgen-responsive LNCaP and-independent PC-3 prostate cancer cells. Nutr Cancer 57, 111-121, 2007.
17. Lee HH, Ho CT, Lin JK: Theaflavin-3,3--digallate and penta-O-galloylbeta- D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 25, 1109-1118, 2004.
18. Leber TM, Balkwill FR: Zymography a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 249, 24-28, 1997.
19. Chen S, Gao J,Halicka HD, Traganos F, Darzynkiewicz Z: Down-regulation of androgen-receptor and PSA by phytochemicals. Int J Oncol 32, 405-411, 2008.
20. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, rapman J: The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5, 1921-1930, 1991.
21. Balk SP, Ko YJ, Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol 21, 383-391, 2003.
22. Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ: In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 19, 975-983, 2005.
23. Nifli AP, Bosson-Kouaḿe A, Papadopoulou N, Kogia C, Kampa M, et al.: Monomeric and oligomeric flavanols are agonists of membrane androgen receptors. Exp Cell Res 309, 329-339, 2005.
24. Harper CE, Patel BB, Wang J, Eltoum IA, Lamartiniere CA: Epigallocatechin-3-gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 67, 1576-1589, 2007.
25. Ren F, Zhang S, Mitchell SH, Butler R, Young CY: Tea polyphenols downregulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19, 1924-1932, 2000.
26. Romero I, Ṕaez A, Ferruelo A, Luj́an M, Berenguer A: Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. BJU Int 89, 950-954, 2002.
27. Vayalil PK, Mittal A, Katiyar SK: Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF kappa B. Carcinogenesis 25, 987-995, 2004.
28. Xing N, Chen Y, Mitchell SH, Young CY: Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22, 409-414, 2001.
29. Yuan H, Gong A, Young CY: Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26, 793-801, 2005. (Pubitemid 41214342)
30. Zierau O, Morrissey C, Watson RW, Schwab P, Kolba S, et al.: Antiandrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl) naringenin and 8-prenylnaringenin. PlantaMed 69, 856-858, 2003.
31. Han HY, Shan S, Zhang X, Wang NL, Lu XP, et al.: Down-regulation of prostate specific antigen in LNCaP cells by flavonoids from the pollen of Brassica napus L. Phytomedicine 14, 338-343, 2007.
32. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H: Modulation of phosphatidylinositol-3-kinase/protein kinase B-and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 91, 232-242, 2004.
33. Kreisberg JI: Signal transduction pathways in androgen-dependent and-independent prostate cancer cell proliferation. Endocr Relat Cancer 12, 119-134.
34. Manin M, Baron S, Goossens K, Beaudoin C, Jean C, et al.: Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 366(Pt. 3), 729-736, 2002.
35. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, et al.: Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663, 2005.
36. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG: Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278, 33753-33762, 2003.
37. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N: Roles of p38-and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiolinduced p53 induction and apoptosis. Carcinogenesis 24, 1067-1075, 2003.
38. Shih A, Zhang S, Cao HJ, Boswell S, Wu YH, et al.: Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. MolCancer Ther 3, 1355-1364, 2004.
39. Lokeshwar BL: MMP inhibition in prostate cancer. Ann NY Acad Sci 878, 271-289, 1999.
40. Brawley OW, Barnes S, Parnes H: The future of prostate cancer prevention. Ann NY Acad Sci 952, 145-152, 2001.
41. Stearns ME, Stearns M: Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 8, 63-67, 1996.
42. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F et al.: In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin ExpMetastas 15, 246-258, 1997.